Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of BW-20805 in Adult Hereditary Angioedema
2024-518207-22-00Phase 2Authorised
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Apr 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of BW-20805 in hereditary angioedema (HAE), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Planned start Apr 2025; status: authorised.
02
Drugs
BW-20805
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2024-518207-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518207-22-00.